| Q92377318 | A Novel Cell-Penetrating Antibody Fragment Inhibits the DNA Repair Protein RAD51 |
| Q39311514 | A novel anti-DR5 chimeric antibody and epirubicin synergistically suppress tumor growth |
| Q57570718 | A prospective cancer chemo-immunotherapy approach mediated by synergistic CD326 targeted porous silicon nanovectors |
| Q34164735 | A review on various targeted anticancer therapies |
| Q60924652 | Anti-CD137 monoclonal antibody enhances trastuzumab-induced, natural killer cell-mediated cytotoxicity against pancreatic cancer cell lines with low human epidermal growth factor-like receptor 2 expression |
| Q36791878 | Antibody Therapeutics in Oncology |
| Q26800175 | Antibody-drug conjugates as novel anti-cancer chemotherapeutics |
| Q38923528 | Antitumor activity of an anti-CD98 antibody. |
| Q35546950 | CD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction |
| Q41612157 | CD55 and CD59 expression protects HER2-overexpressing breast cancer cells from trastuzumab-induced complement-dependent cytotoxicity |
| Q39958332 | Cancer immunotherapy. |
| Q37453154 | Cell surface-associated anti-MUC1-derived signal peptide antibodies: implications for cancer diagnostics and therapy |
| Q36189447 | Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions. |
| Q47659258 | Combinatorial genome and protein engineering yields monoclonal antibodies with hypergalactosylation from CHO cells. |
| Q39314271 | Comparative study of the three different fluorophore antibody conjugation strategies |
| Q92441177 | Development of Human Monoclonal Antibody for Claudin-3 Overexpressing Carcinoma Targeting |
| Q37206247 | EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy |
| Q91971862 | Effects of N-Glycosylation on the Structure, Function, and Stability of a Plant-Made Fc-Fusion Anthrax Decoy Protein |
| Q43278365 | Electrospray ionization quadrupole ion-mobility time-of-flight mass spectrometry as a tool to distinguish the lot-to-lot heterogeneity in N-glycosylation profile of the therapeutic monoclonal antibody trastuzumab. |
| Q89992520 | Enhancement of sialylation in rIgG in glyco-engineered Chinese hamster ovary cells |
| Q37638935 | EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma |
| Q36377940 | Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab |
| Q58724935 | Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies |
| Q38799374 | Fcγ1 fragment of IgG1 as a powerful affinity tag in recombinant Fc-fusion proteins: immunological, biochemical and therapeutic properties. |
| Q42218820 | FcγR and EGFR polymorphisms as predictive markers of cetuximab efficacy in metastatic colorectal cancer |
| Q37066000 | Glycoengineering of human IgG1-Fc through combined yeast expression and in vitro chemoenzymatic glycosylation |
| Q35839942 | High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma |
| Q42660155 | Human Antibody Fusion Proteins/Antibody Drug Conjugates in Breast and Ovarian Cancer |
| Q33576327 | Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies |
| Q51081577 | Integrated Genome and Protein Editing Swaps α-2,6 Sialylation for α-2,3 Sialic Acid on Recombinant Antibodies from CHO. |
| Q39077167 | KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells |
| Q37819809 | Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier |
| Q49724715 | Natural Killer Cell-Based Immunotherapy in Gynecologic Malignancy: A Review. |
| Q35057971 | Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (removab). |
| Q56900749 | Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CP-675,206), a fully human monoclonal antibody |
| Q49672464 | Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human Carcinomas |
| Q33388660 | Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors |
| Q99577321 | SPECT imaging of distribution and retention of a brain-penetrating bispecific amyloid-β antibody in a mouse model of Alzheimer's disease |
| Q92255544 | Structure and Optimization of Checkpoint Inhibitors |
| Q90862850 | Targeted therapeutic options and future perspectives for HER2-positive breast cancer |
| Q37206241 | Targeting cancer stem cells with monoclonal antibodies: a new perspective in cancer therapy and diagnosis |
| Q46026271 | The emerging therapeutic role of antibody mixtures. |
| Q64264660 | The evolving role of immuno-oncology for the treatment of head and neck cancer |
| Q38052616 | Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients |
| Q37957140 | Use of allogeneic NK cells for cancer immunotherapy. |